Thymic carcinoma

Real World Data Shows Impact of Immunotherapy in Populations Underrepresented in Clinical Trials, According to JNCCN Study

Retrieved on: 
Monday, December 11, 2023
Case Comprehensive Cancer Center, Assistant, Associate, Research, Safety, NCCN, Progression-free survival, Thymic carcinoma, White, National Comprehensive Cancer Network, Disease, Insurance, Patient, Pembrolizumab, Lung cancer, BMI, ECOG, MPH, Survival, Doctor of Philosophy, Immunotherapy, Chemotherapy, NSCLC, Birth control, Medical imaging, Pharmaceutical industry, Medicine, MD, Oncology

PLYMOUTH MEETING, Pa., Dec. 11, 2023 /PRNewswire/ -- New research in the December 2023 issue of JNCCN—Journal of the National Comprehensive Cancer Network finds patients treated with first-line immunotherapy for advanced Non-Small Cell Lung Cancer (NSCLC) showed similar results in terms of survival, progression-free survival, and treatment duration, regardless of race or ethnicity, even with differences in income and insurance. The clinical investigators focused on patients in under-represented groups who were typically less likely to be included in the immunotherapy clinical trials that have been conducted to date. They analyzed results from 248 patients treated with pembrolizumab over a 9-year period between January 1, 2013 and June 1, 2022, with non-Hispanic Black, Hispanic, and Non-Hispanic White patients each accounting for an approximately equal percentage. Median overall survival was 16.8 to 26.3 months, similar to results previously reported in large prospective clinical trials.

Key Points: 
  • The clinical investigators focused on patients in under-represented groups who were typically less likely to be included in the immunotherapy clinical trials that have been conducted to date.
  • Median overall survival was 16.8 to 26.3 months, similar to results previously reported in large prospective clinical trials.
  • This study could change how we take care of patients and plan future lung cancer studies to better include all patients.
  • "There is a clear need for future studies to include underrepresented patient groups in clinical trials to validate these findings and to better guide clinical practice."

Promontory Therapeutics Announces Preliminary Data from the National Cancer Institute Phase 2 Clinical Trial of PT-112 in Thymoma and Thymic Carcinoma at 2023 ASCO Annual Meeting

Retrieved on: 
Friday, June 2, 2023
Thermal power stations in Russia and Soviet Union, Lead, Bangladesh Technical Education Board, ASCO, Thymoma, National Cancer Institute, American Society of Clinical Oncology, Patient, Annual general meeting, Thymic carcinoma, Therapy, NCI, Society, Safety, Pharmaceutical industry, MD

The trial is being conducted under formal collaboration with the National Cancer Institute (NCI), part of the National Institutes of Health (see NCT05104736 ).

Key Points: 
  • The trial is being conducted under formal collaboration with the National Cancer Institute (NCI), part of the National Institutes of Health (see NCT05104736 ).
  • The data were published online in an abstract for the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.
  • "Based on preliminary data to date, PT-112 appears to be safe and tolerable, and clinically active in patients with recurrent TETs.
  • The initial translational evidence of PT-112 immune activation is encouraging and supportive of further investigation," said Promontory Therapeutics Chief Medical Officer Johan Baeck, MD.

Promontory Therapeutics Appoints Two Experienced Executives to Its Core Management Team

Retrieved on: 
Tuesday, September 13, 2022
Merck Group, CMC, Trial of the century, LLC, Promontory, Fellow, Shea, NEW, Prostate, AMAG Pharmaceuticals, Damage-associated molecular pattern, Thymic carcinoma, Ferris, Industry, Therapy, Merck Serono, ICD, NCI, Control, ARIAD Pharmaceuticals, Dartmouth College, Doctor of Philosophy, Orphan drug, Drug development, Albemarle Corporation, Immunogenic cell death, Kate, Lung, Tumor microenvironment, Research, B cell, Texas A&M University, Pharmaceutical industry, Science, Chemistry, IQVIA, Organic chemistry

NEW YORK, Sept. 13, 2022 /PRNewswire/ -- Promontory Therapeutics Inc., a clinical stage pharmaceutical company advancing small molecule immunotherapies in oncology, today announced the appointments of Helene Shea, PhD, as Vice President of Chemistry, Manufacturing and Controls (CMC), and Kate Hogg Call as Vice President of Clinical Operations.

Key Points: 
  • "We could not be more pleased to add Helene and Kate's collective strengths to our team."
  • "Promontory is at a critical inflection point where clinical trials are expanding globally, and drug supply must scale accordingly.
  • Promontory Therapeutics Inc. is a privately held, clinical stage pharmaceutical company focused on small molecule immunotherapy.
  • To learn more about Promontory Therapeutics, visit the company's website here .

GenFleet Therapeutics to Present Data from Phase I Trial of GFH018 Monotherapy at the 2022 European Society for Medical Oncology Annual Meeting

Retrieved on: 
Wednesday, September 7, 2022
Lung cancer, Neoplasm, European Society for Medical Oncology, Metastasis, Mexican Federal Highway 14D, Cancer, Malignancy, Trial of the century, Gene, IND, Therapy, Pancreatic cancer, Thymic carcinoma, Toxic leukoencephalopathy, Poster, Hope, Glioma, Blood, ESMO, Hepatocellular carcinoma, Prognosis, Half-life, PD-1, Squamous cell carcinoma, EMT, Immunology, Fibrosis, Oncology, IP, Colorectal cancer, Patient, Pharmaceutical industry

Two phase II combination studies of GFH018 with PD-1 inhibitor are ongoing with additional data to be presented at medical meetings in the future.

Key Points: 
  • Two phase II combination studies of GFH018 with PD-1 inhibitor are ongoing with additional data to be presented at medical meetings in the future.
  • We are pleased to report the preliminary efficacy signal and good safety/tolerability profile of GFH018 monotherapy and look forward to the further trials in combination studies."
  • Developed by GenFleet Therapeutics, GFH018 is an orally administered TGF- R1 inhibitor and entered into phase I clinical trial in 2019.
  • GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies, is dedicated to serving significant global unmet medical needs in oncology and immunology.

New Nonprofit Foundation Makes a Huge Impact on Rare Cancer

Retrieved on: 
Monday, July 11, 2022
Survival, TCC, Biology, Thymic cancer, Caregiver, Thymic carcinoma, Profile, Hope, Disease, Education, Survival rate, Neoplasm, Thymus, Cornell University, TET, Weill Cornell Medicine, Cancer, Research, Patient, Biomedical Research, Diagnosis, Pharmaceutical industry

OLATHE, Kan., July 11, 2022 /PRNewswire/ -- Joan & Sanford I. Weill Medical College of Cornell University ("Weill Cornell") located in New York, NY has been awarded $240,000 over a 2-year period from the Thymic Carcinoma Center headquartered in Olathe, Kansas for the development of new models of Thymic Epithelial Tumors (TET's). This research will provide novel preclinical models of human thymic tumors. These models are essential for better understanding the biology of these tumors, identifying unique targets, and testing novel therapies for Thymic Cancers. "Thymic Carcinoma Center is committed to providing Thymic Carcinoma patients with education, cancer wellness, and financial assistance as well as funding critical biomedical research within the medical community. "We are excited and committed to providing these much-needed funds for the research of Thymic Cancers, given its rarity, research surrounding these cancers is often underfunded," says Michael Delaney, President & Executive Director of Thymic Carcinoma Center.

Key Points: 
  • "Thymic Carcinoma Center is committed to providing Thymic Carcinoma patients with education, cancer wellness, and financial assistance as well as funding critical biomedical research within the medical community.
  • Thymic Carcinoma is a rare form of cancer that affects the Thymus gland.
  • Although rare, this form of cancer is very aggressive with a 5-year survival rate of 25-30%.
  • We aim to support their journey through our core values of education, cancer wellness, patient financial assistance, and medical research.

Phosplatin Therapeutics Adopts New Corporate Name as Promontory Therapeutics Inc.

Retrieved on: 
Thursday, May 5, 2022
Avelumab, CRADA, Immunogenic cell death, Merck Group, Thymic carcinoma, PD, Company, ICD, Trial of the century, Damage-associated molecular pattern, Large-cell lung carcinoma, Therapy, Merck Serono, Thymoma, Coronavirus Scientific Advisory Board (Turkey), B cell, Research, Growth, Cancer, NCI, Pharmaceutical industry

NEW YORK, May 5, 2022 /PRNewswire/ -- Phosplatin Therapeutics Inc., a clinical stage pharmaceutical company focused on oncology therapeutics, today announced that the Company has changed its name to Promontory Therapeutics Inc. ("Promontory").

Key Points: 
  • NEW YORK, May 5, 2022 /PRNewswire/ -- Phosplatin Therapeutics Inc., a clinical stage pharmaceutical company focused on oncology therapeutics, today announced that the Company has changed its name to Promontory Therapeutics Inc. ("Promontory").
  • The new name reflects the Company's growth and evolution, and its goal to become the leading company within oncology therapeutics advancing small molecule immunotherapies.
  • Promontory is led by a strong management team, board of directors, and Scientific Advisory Board with in-depth industry knowledge.
  • Promontory Therapeutics Inc. is a privately held, clinical stage pharmaceutical company developing small molecule immunotherapies.

Knight Therapeutics Inc. Announces Approval of Lenvima® in Colombia

Retrieved on: 
Tuesday, January 4, 2022
RET, Pembrolizumab, Sorafenib, HIV disease progression rates, Hepatocellular carcinoma, FGF, RCC, GLOBE, KDR, VEGFR1, Nature, Thymic carcinoma, Radiation, Liver cancer, Progression-free survival, Lenvatinib, KIT, Annual report, Everolimus, Therapy, VEGFR3, Thyroid cancer, Adult, Patient, FLT1, GUD, Iodine, Laboratorio museotecnico Goppion, Intention, Cancer, Renal cell carcinoma, VEGF, FLT4, TSX, Pharmaceutical industry, Knight, Uniting Medically Supervised Injecting Centre, Eisai

In addition, Lenvima (lenvatinib) was statistically significantly superior to sorafenib for progression-free survival and objective response rate.

Key Points: 
  • In addition, Lenvima (lenvatinib) was statistically significantly superior to sorafenib for progression-free survival and objective response rate.
  • In 2020, there were approximately 5,3043 new patients with thyroid cancer and 2,2893 new patients with liver cancer in Colombia.
  • Were pleased to announce the approval of Lenvima (lenvatinib) in Colombia as it provides a new treatment option for radioiodine refractory differentiated thyroid cancer and unresectable hepatocellular carcinoma, said Samira Sakhia, President & Chief Executive Officer.
  • Factors and risks, which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.'s Annual Report and in Knight Therapeutics Inc.'s Annual Information Form for the year ended December 31, 2020 as filed on www.sedar.com .

Phosplatin Therapeutics Collaborates with the National Cancer Institute For Phase 2 Proof of Concept Study of PT-112 in Thymoma and Thymic Carcinoma

Retrieved on: 
Monday, November 15, 2021
Family, Population, Safety, Thorax, Thymic carcinoma, ICD, Cancer, PD-L1, Merck Serono, Therapy, MD, Thymoma, Immunogenic cell death, Clinical trial, Drug resistance, Damage-associated molecular pattern, Congress, National, NCI, ASH, Trial of the century, B cell, Cooperative research and development agreement, Immunotherapy, ESMO, Research, Tumor microenvironment, Lead, Thermal power stations in Russia and Soviet Union, Neoplasm, National Cancer Institute, Development, César Award for Best Poster, Large-cell lung carcinoma, NSCLC, CRADA, Merck Group, Toxicity, Patient, Development of the human body, FDA, IND, Pharmaceutical industry

Phosplatin and NCI anticipate opening the Phase 2 study soon, under a recently approved investigational new drug (IND) application.

Key Points: 
  • Phosplatin and NCI anticipate opening the Phase 2 study soon, under a recently approved investigational new drug (IND) application.
  • Phosplatin will provide NCI with PT-112 drug supply and support correlative research, and NCI will oversee enrollment and care of the study's intended 49 patients.
  • "Thymoma and thymic carcinoma are rare forms of cancer for which there is currently no FDA approved treatment.
  • The Phase 1 study in patients with relapsed or refractory multiple myeloma presented at ASH is the third completed Phase 1 study of PT-112.

Lenvima (Lenvatinib) Approved for Additional Indication of Unresectable Thymic Carcinoma in Japan

Retrieved on: 
Tuesday, March 23, 2021
Orphan drugs, Chemical compounds, Organic compounds, Drugs, Chloroarenes, Ureas, Protein kinase inhibitors, Cyclopropanes, Lenvatinib, Merck & Co., Eisai, Thymic carcinoma

TOKYO, Mar 23, 2021 - (JCN Newswire) - Eisai Co., Ltd. and MSD K.K., a subsidiary of Merck & Co., Inc., Kenilworth, N.J., U.S.A., announced today that LENVIMA (generic name: lenvatinib mesylate), the multiple receptor tyrosine kinase inhibitor discovered by Eisai, has been approved in Japan for the additional indication of treatment of unresectable thymic carcinoma.

Key Points: 
  • TOKYO, Mar 23, 2021 - (JCN Newswire) - Eisai Co., Ltd. and MSD K.K., a subsidiary of Merck & Co., Inc., Kenilworth, N.J., U.S.A., announced today that LENVIMA (generic name: lenvatinib mesylate), the multiple receptor tyrosine kinase inhibitor discovered by Eisai, has been approved in Japan for the additional indication of treatment of unresectable thymic carcinoma.
  • This marks the first approval for LENVIMA for unresectable thymic carcinoma in Japan.
  • For unresectable thymic carcinoma, platinum-based first-line therapy is recommended.
  • In June 2020, LENVIMA received orphan drug designation in Japan for unresectable thymic carcinoma.

Eisai: Application for Additional Indication of Anti Cancer Agent Lenvima for Unresectable Thymic Carcinoma Submitted in Japan

Retrieved on: 
Friday, July 31, 2020
Orphan drugs, Organic compounds, Chemical compounds, Chloroarenes, Ureas, Chemistry, Cyclopropanes, Lenvatinib, Protein kinase inhibitor, Thymic carcinoma

a subsidiary of Merck & Co., Inc., Kenilworth, N.J., U.S.A., announced today that Eisai has submitted an application in Japan for the additional indication of treatment of unresectable thymic carcinoma for multiple receptor tyrosine kinase inhibitor LENVIMA (generic name: lenvatinib mesylate).

Key Points: 
  • a subsidiary of Merck & Co., Inc., Kenilworth, N.J., U.S.A., announced today that Eisai has submitted an application in Japan for the additional indication of treatment of unresectable thymic carcinoma for multiple receptor tyrosine kinase inhibitor LENVIMA (generic name: lenvatinib mesylate).
  • In June 2020, LENVIMA received orphan drug designation in Japan for unresectable thymic carcinoma.
  • This application is based on the results of an open-label, single-arm, multicenter, investigator-initiated clinical phase II study (NCCH1508) conducted in Japan, evaluating LENVIMA as a single agent in 42 patients with thymic carcinoma previously treated with at least one platinum-based regimen.
  • This study met its endpoint as the lower value of the CI exceeded the pre-specified statistical criteria, a threshold ORR of 10%.